Encouragingly, ongoing trials, such as EVOKE and EVOKE+, are already exploring this potential for early Alzheimer's disease
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%
Srenson's thinking was coloured by the fact that a previous drug, Redux, approved in 1996 by the FDA for weight loss and launched with great fanfare, had to be withdrawn a year later after it was found to cause major heart attacks and to be largely ineffective
For anyone making a decision today, the comparison is lopsided in one specific sense: tirzepatide is an option you can actually be prescribed, with an approved label, a regulated supply chain, and accumulating post-market safety data
Frequently Asked Questions Does microdosing GLP-1 medication prevent Alzheimers disease